The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.
about
Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritisAuditory dysfunction in schizophrenia: integrating clinical and basic features.The Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte Differentiation In Vitro and Neuroprotection During the Cuprizone-Induced Central Nervous System Demyelination.Long-term consequences of adolescent cannabinoid exposure in adult psychopathology.To Break or to Brake Neuronal Network Accelerated by Ammonium Ions?Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice.The Influence of the CB1 Receptor Ligands on the Schizophrenia-Like Effects in Mice Induced by MK-801The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders.The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.Regulation of neuronal communication by G protein-coupled receptors.Cannabinoids: Glutamatergic Transmission and Kynurenines.Pharmacological Modulation of the Sigma 1 Receptor and the Treatment of Pain.Polyunsaturated fatty acids and endocannabinoids in health and disease.Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on MigraineNeuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: involvement of CB1 and NMDA receptors.The Role of BK Channels in Antiseizure Action of the CB1 Receptor Agonist ACEA in Maximal Electroshock and Pentylenetetrazole Models of Seizure in MiceEndocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction.Neurofunctional changes in adolescent cannabis users with and without bipolar disorder.Schizophrenia and depression, two poles of endocannabinoid system deregulation.URB597 and the Cannabinoid WIN55,212-2 Reduce Behavioral and Neurochemical Deficits Induced by MPTP in Mice: Possible Role of Redox Modulation and NMDA Receptors.Cannabinoid-glutamate interactions in the regulation of food intake in neonatal layer- type chicks: role of glutamate NMDA and AMPA receptors.The Endocannabinoid System across Postnatal Development in Transmembrane Domain Neuregulin 1 Mutant Mice.Endocannabinoid activation of CB1 receptors contributes to long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation.Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.Sigma-1 Receptor and Pain.The Role of Cannabis within an Emerging Perspective on Schizophrenia
P2860
Q26783956-5BB3843A-A970-4A11-AF50-8496FDFFE5A8Q26796401-675C15E5-3A8A-4E60-B9B4-4CBC8C23E210Q30370881-4E9F7C49-1044-46D6-909A-9F7FAE550DCCQ30424669-15FAD8B1-3479-45B5-9342-537E035D398FQ35719137-1FA79D99-1ABF-4A9E-9065-34129CB4D9E2Q35939665-398C5518-42C3-470C-BC81-F2D9335A19AEQ37306525-04F019D9-8DFF-4E2B-989F-B422F94107DCQ38262682-FBFE53B4-82EE-4DD8-A0EF-81162862E70AQ38317405-F1D6577E-33DA-487B-94A4-C99CB1BD7932Q38484504-097C9C7B-041D-4B0F-8F92-6689425DB641Q38819251-9514B5ED-ACEB-4CC2-A1C3-1CD83F75F5EDQ38896666-E1D5F614-4267-4C6E-A0DF-564609E398BFQ39421016-0242CCA5-E581-4C20-8BB1-64C9ACB6E982Q41572995-4027318A-A5CF-4C2B-B85D-50290DF273B2Q41969953-31017B53-F835-432E-83CB-784253AB5D08Q42141848-8D6BAC1F-9FE2-4F4B-B7F0-237B5B47C9F6Q42317501-C4C8A9E3-0F40-4DB7-A4F3-8DD42A549E46Q44011821-81C3D3FD-7D60-4E20-9E9D-80A8BEB08208Q47284001-08D06567-7BE0-4A8A-9139-FEF2D6EE8E6AQ48355383-36C8EBB4-5046-4374-9AC5-FE094F3A560EQ48820966-6E6400B3-F6C6-40A7-9489-8B6B01563381Q50326139-D3B898B3-7E21-4D76-B3D2-33621DDFFF98Q50942690-84CDBEDD-08FA-4F48-870E-B01FE3DB5EE6Q52625218-A4034CB6-C741-4905-BF88-33E23813E8FCQ53647635-DBE094F0-86FD-44E8-961C-5717C3032378Q58794814-D9BA24F0-BC38-4759-9737-5E46CC9FD87F
P2860
The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The cannabinoid receptor 1 ass ...... n psychosis and schizophrenia.
@ast
The cannabinoid receptor 1 ass ...... n psychosis and schizophrenia.
@en
The cannabinoid receptor 1 ass ...... n psychosis and schizophrenia.
@nl
type
label
The cannabinoid receptor 1 ass ...... n psychosis and schizophrenia.
@ast
The cannabinoid receptor 1 ass ...... n psychosis and schizophrenia.
@en
The cannabinoid receptor 1 ass ...... n psychosis and schizophrenia.
@nl
prefLabel
The cannabinoid receptor 1 ass ...... n psychosis and schizophrenia.
@ast
The cannabinoid receptor 1 ass ...... n psychosis and schizophrenia.
@en
The cannabinoid receptor 1 ass ...... n psychosis and schizophrenia.
@nl
P2860
P921
P356
P1476
The cannabinoid receptor 1 ass ...... in psychosis and schizophrenia
@en
P2093
Javier Garzón
P2860
P356
10.3389/FPHAR.2013.00169
P577
2014-01-02T00:00:00Z